Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL). Update February 2021

Grössmann, N. (2020): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL). Update February 2021. Oncology Fact Sheet Nr. 27.

[thumbnail of Oncology Fact Sheet Nr.27_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
93kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Oncology Fact Sheet Nr. 27
Deposited on:	18 Nov 2020 11:50
Last Modified:	10 Jul 2025 11:30

Repository Staff Only: item control page